High-dose immunosuppressant drug may reduce disability in MS patients

Treatment with high doses of the immunosuppressant drug cyclophosphamide appears to reduce disease activity and disability in individuals with aggressive multiple sclerosis, according to an article posted online today that will appear in the August 2008 print issue of Archives of Neurology.

Multiple sclerosis (MS) is an inflammatory disease in which the protective coating covering nerve cells degenerates, presumably because of autoimmune causes (in which the body attacks itself), according to background information in the article. Four subtypes of MS have been identified, each with a distinct autoimmune process. Because of these different disease types, immune-related therapies to treat MS have been suboptimal.

Cyclophosphamide, which affects the function of immune cells known as T and B cells, has been used to treat MS with mixed results. It is often combined with bone marrow transplantation. Chitra Krishnan, M.H.S., of the Bloomberg School of Public Health, Johns Hopkins University, Baltimore, and colleagues studied high doses of the drug without bone marrow transplantation in a two-year open-label trial involving nine patients (six men, three women, average age 35) with aggressive relapsing-remitting MS. Relapsing-remitting is the most common type of MS, in which patients experience periods of symptoms followed by periods of symptom-free remission. The patients received 50 milligrams per kilogram per day of cyclophosphamide intravenously for four consecutive days.

Over an average of 23 months of follow-up, there were no deaths or unexpected or serious adverse events. The patients experienced an average 39.4 percent reduction in disability and an 87 percent improvement in scores on a composite test measuring physical and mental function. In addition, magnetic resonance imaging (MRI) showed a decrease in the average number of MS-related brain lesions, from 6.5 to 1.2 lesions.

"High-dose cyclophosphamide treatment of patients with aggressive MS was safe and well tolerated and did not lead to excess morbidity or accelerated brain atrophy," the authors write. "Moreover, high-dose cyclophosphamide induced a functional improvement in most of the patients we studied. In many of those patients, the functional improvement was sustained through the length of the study (up to 24 months) despite the absence of any immunomodulatory therapies beyond the initial high-dose cyclophosphamide treatment."

Source: JAMA and Archives Journals

Related stories:

Increased incidence of melanoma found in rheumatoid arthritis patients treated with methotrexate
A chronic, inflammatory disease of unknown origin, rheumatoid arthritis (RA) affects about 1 percent of adults worldwide. Marked by joint destruction, RA often leads to disability and diminished quality of life. It can also lead to an early death from cancer. Various studies have linked RA to an increased risk of Hodgkin's and non-Hodgkin's lymphoma, leukemia, myeloma, and lung cancer.
Computerized reminder system drove up colon cancer screening rates, study found
A computerized reminder system used in community-based primary care doctors' offices increased colorectal cancer screening rates by an average of 9 percent, according to a new study from the University of Michigan Health System.
Studies spot numerous undiscovered gene alterations in pancreatic and brain cancers
HHMI investigators have detected a multitude of broken, missing, and overactive genes in pancreatic and brain tumors, in the most detailed genetic survey yet of any human tumor. Some of these genetic changes were previously unknown and could provide new leads for improved diagnosis and therapy for these devastating cancers.
Bisphenol A linked to metabolic syndrome in human tissue
New research from the University of Cincinnati (UC) implicates the primary chemical used to produce hard plastics—bisphenol A (BPA)—as a risk factor for metabolic syndrome and its consequences.
Potential remedy for the 'mental fog' in cancer patients
Cancer patients have complained for years about the mental fog known as chemobrain. Now in animal studies at West Virginia University (WVU), researchers have discovered that injections of N-acetyl cysteine (NAC), an antioxidant, can prevent the memory loss that breast cancer chemotherapy drugs sometimes induce. The WVU researchers' study has just been published in the September issue of the Springer journal Metabolic Brain Disease.
Study: No link between measles vaccine and autism
(AP) -- New research further debunks any link between measles vaccine and autism, work that comes as the nation is experiencing a surge in measles cases fueled by children left unvaccinated.
Study: New way to spot breast cancer shows promise
(AP) -- A radioactive tracer that "lights up" cancer hiding inside dense breasts showed promise in its first big test against mammograms, revealing more tumors and giving fewer false alarms, doctors reported Wednesday. The experimental method - molecular breast imaging, or MBI - would not replace mammograms for women at average risk of the disease.
Too much calcium in blood may increase risk of fatal prostate cancer
Men who have too much calcium in their bloodstreams may have an increased risk of fatal prostate cancer, according to a new analysis from Wake Forest University School of Medicine and the University of Wisconsin.

News discussion:

Medicine & Health news